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DHA, an omega-3 fatty acid, is an important constituent of brain membranes and 
has a key role in brain development and function. This review aims to highlight 
recent research on DHA’s role during age-related cognitive decline and Alzheimer’s 
disease. Animal and in vitro studies have provided some interesting mechanistic leads, 
especially on brain glucose metabolism, that may be involved in neuroprotection 
by DHA. However, results from human studies are more mitigated, perhaps due to 
changing DHA metabolism during aging. Recent innovative tools such as 13C-DHA 
for metabolic studies and 11C-DHA for PET provide interesting opportunities to study 
factors that affect DHA homeostasis during aging and to better understand whether 
and how to use DHA to delay or treat Alzheimer’s disease.
Keywords:  aging • Alzheimer’s disease • apoE • brain glucose metabolism • cognitive 
decline • docosahexaenoic acid • metabolism • omega-3 fatty acids
Alzheimer’s disease (AD) is the most common 
form of age-related cognitive decline in West-
ern countries [1] and is characterized by a pro-
gressive loss of memory that affects daily living 
activities. The main neuropathological features 
of AD are the accumulation of senile plaques, 
the presence of neurofibrillary tangles, regional 
brain atrophy and a regional hypometabolism 
of glucose. In the absence of typical features 
of AD, individuals with cognitive decline 
greater than expected during normal aging 
are defined as having mild cognitive impair-
ment (MCI) [2]. About 50% of MCI progress 
to AD within 5 years. With increasing life 
expectancy, age-related cognitive decline has 
become a major concern for healthcare poli-
cies and research. Age is the most important 
risk factor for AD, but the sporadic form of 
AD is also associated with genetic risk factors, 
especially carrying the APOE4 allele [3], higher 
risk in women, comorbidities, such as diabetes, 
hypertension and cardiovascular disease [1] and 
poor lifestyle, including sedentarity, stress and 
poor nutrition [4,5].
No pharmacological treatment is currently 
available to cure AD. Modifying lifestyle 
habits to delay the onset of AD has attracted 
special attention, especially strategies that 
improve nutrition and physical activity. Due 
to their central position within the central 
nervous system, omega-3 polyunsaturated 
fatty acids (PUFA) may be good candidates 
to promote cognitive health during aging. 
Indeed, omega-3 PUFA, especially docosa-
hexaenoic acid (DHA), are important com-
ponents of all cell membranes [6] and play 
a critical role in optimal brain development 
and function [7]. This review aims to update 
the potential protective role of dietary DHA 
intake in age-related cognitive decline which 
has been intensively investigated over the 
past decade. First, we will describe a selec-
tion of the evidence from in vitro and animal 
studies highlighting the protective role of 
omega-3 PUFA against some neuropatholog-
ical features of age-related cognitive decline, 
especially glucose hypometabolism. Then we 
will discuss the results obtained from human 
studies, especially the divergence of results 
obtained from epidemiological studies and 
randomized clinical trials (RCT). Finally, we 
will highlight some metabolic features that 
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may need to be taken into account in clinical trials to 
better understand the metabolism of omega-3 PUFA 
during aging and age-related cognitive decline and to 
adapt dietary recommendations in this population.
Omega-3 fatty acids & the neuropathology 
of Alzheimer’s disease: evidence from 
in vitro & animal studies
Senile plaques
The most important neuropathological hallmark of 
age-related cognitive decline is the formation of senile 
plaques through the aggregation of β amyloid (Aβ) 
peptides, resulting from the amyloidogenic cleav-
age of amyloid precursor protein (APP) [1]. In vitro 
and animal studies have shown that providing DHA 
decreases Aβ accumulation and neurotoxicity [8–10] 
in cells implicated in the neurovascular unit, in other 
words, neurons, glial cells, endothelial cells and 
pericytes [11]. DHA inhibits β-secretase activity and 
promotes α-secretase stability, leading to the inhibi-
tion of amyloidogenic pathway in favor of the non-
amyloidogenic pathway [12]. DHA also stimulates the 
phagocytosis of Aβ42 by microglia [13] and inhibits the 
oligomerization and fibrillation of Aβ peptides [14,15]. 
DHA regulation of the amyloidogenic pathway also 
implicates membrane lipid rafts. The immediate envi-
ronment of lipid rafts is highly enriched in cholesterol 
and favors the interaction between APP and β-secretase 
and, hence, Aβ accumulation [16]. DHA reduces cho-
lesterol biosynthesis and promotes a delocalization of 
cholesterol from lipid rafts to nonrafts membrane frac-
tions [12]. Part of the protective effect of DHA against 
Aβ neurotoxicity seems also to be mediated through 
its hydroxyl-derivative, as shown in vitro with the 
natural derivative, neuroprotectin D1 (NPD1) [17,18] or 
synthetic forms of NPD1 [19].
Neurofibrillary tangles & Tau 
hyperphosphorylation
AD neuropathology is also characterized by the pres-
ence of neurofibrillary tangles, composed of abnormally 
hyperphophorylated Tau proteins [1]. Under physi-
ological conditions, Tau proteins bind to microtubules 
to ensure their stability. The hyperphosphorylation of 
Tau proteins occurring during AD prevents them from 
binding to microtubules and so contributes to micro-
tubule disassembly. Studies in mouse models of AD 
show that supplementation with DHA [20], hydroxyl-
derivative of DHA [19], as well as endogenous conver-
sion of n-6 PUFA to omega-3 PUFA in fat-1 mouse 
model [21] all reduce Tau accumulation and phos-
phorylation. This effect may go through the inactiva-
tion of c-Jun N-terminal kinase, a kinase implicated 
in Tau phosphorylation [20,22]. Interestingly, DHA 
also promotes the expression of cytoskeletal proteins 
associated with stable and dynamic microtubules in 
primary rat hippocampal neurons [23].
Brain glucose hypometabolism
Regional brain glucose hypometabolism on the order 
of 10–15% occurs in healthy aging in the absence 
of any measurable cognitive decline [24–26]. In AD, 
brain glucose hypometabolism is more severe reaching 
upwards of 35% in some brain areas [27]. There is a 
positive association between glucose hypometabolism 
and the degree of cognitive decline in MCI or AD 
patients [28,29]. Brain glucose hypometabolism may be 
a consequence of neural degeneration and synaptic loss 
associated with AD. However, it is also clearly present 
in cognitively normal individuals with risk factors for 
AD, in other words, aging, family history of AD or 
prediabetes, so may also be contributing to the cause 
of AD [30].
We have recently shown in rats that a low DHA 
content in brain induced by feeding a diet deficient in 
omega-3 PUFA is associated with lower glucose uptake 
by the brain. 18F-fluorodeoxyglucose (18F-FDG) posi-
tron emission tomography (PET) was used to deter-
mine glucose uptake expressed as standardized uptake 
values (SUVs). Two-month-old male Wistar rats 
received either an omega-3 PUFA deficient diet (1370 
mg LA and 6 mg ALA/100 g of diet) or a control diet 
supplying adequate amount of omega-3 PUFA (1307 
mg LA and 309 mg ALA/100 g of diet). The omega-3 
PUFA deficiency was associated with a 60% reduction 
in brain phospholipid DHA and a significant decrease 
of glucose utilization in the brain corresponding to 
both a reduction of the rate of FDG input during 
the early phase (27% lower than in controls) and a 
lower plateau level of FDG incorporation (12% lower 
SUVmax) (Figure 1). Brain glucose uptake is highly 
dependent on glucose transporter activity, especially 
GLUT1, which is localized in both endothelial cells 
of the blood–brain barrier and astrocytes [31]. Interest-
ingly, omega-3 PUFA deficiency in rats reduces gene 
and protein expression of GLUT1 [32,33], without 
changing other glucose transporters such as the neuro-
nal GLUT3 isoform. In vitro studies on rat brain endo-
thelial cells depleted of DHA show that the incorpora-
tion of DHA in cell membranes by its addition in the 
culture medium led to a 35% increase in glucose trans-
port activity associated with an increase in GLUT1 
density [34,35]. Altogether, these results suggest an 
important role of omega-3 PUFA in the regulation of 
brain glucose metabolism, in part due to the regulation 
of the endothelial and astroglial GLUT1. Modulating 
DHA dietary intakes may therefore help to prevent or 
correct the glucose hypometabolism observed during 
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age-related cognitive decline [36]. Nevertheless, a small, 
short-term pilot study showed that a 3-week fish oil 
supplementation providing daily 680 mg of DHA 
and 323 mg of EPA was not sufficient to alter brain 
FDG uptake in older persons despite them having mild 
glucose intolerance [37].
Omega-3 fatty acids & prevention of 
age-related cognitive decline in humans: 
epidemiological studies vs clinical trials
Fish & dietary docosahexaenoic acid 
intakes: results from cross-sectional 
& prospective studies
The endogenous synthesis of DHA from its dietary 
essential precursor, α-linolenic acid, is very low in 
humans [38]. Providing sufficient amount of DHA 
through dietary intakes, especially through the con-
sumption of fatty fish, is therefore recommended to 
ensure the optimal bioavailability of DHA to the 
tissues, notably to the brain. A number of cross-
sectional and prospective studies have highlighted a 
positive correlation between fish and/or DHA dietary 
consumption and cognitive performances in healthy 
elderly [39–42], as well as with lower accumulation of 
Aβ peptides [43] and lower brain atrophy [44,45]. Com-
pared with individuals with MCI or AD, cognitively 
healthy elderly tend to consume higher amount of 
fatty acid and/or DHA [46–49], an observation that 
agrees with prospective studies showing an inverse 
correlation between fish consumption and the inci-
dence of dementia, especially AD [50–54]. Consuming 
fatty fish at least once a week may therefore help 
reduce the risk to develop AD by more than 50% [52].
Although many epidemiological studies suggest a 
protective role of fish and/or DHA consumption on 
the incidence of age-related cognitive decline, three 
prospective studies do not show any significant asso-
ciation between higher fish consumption and risk of 
AD. The first study was based on a subsample of par-
ticipants and may have a lack of statistical power, the 
association between fish consumption and a reduc-
tion of the risk of AD bordering on significant [55]. In 
the Rotterdam study, the 2-year follow-up reported a 
protective role of fish consumption against the risk of 
AD, but this result was no longer found in the 6- and 
10- year follow-up of the same cohort [56,57]. In this 
study, the consumption of fish was quite low and con-
sisted principally of lean fish that are not particularly 
rich in omega-3 PUFA. Moreover, the APOE poly-
morphisms may need to be considered in the statisti-
cal models since three studies have shown that the 
relationship between higher consumption of fish and 
lower risk of AD is reduced or absent in carriers of 
APOE4 [53–54,58].
Docosahexaenoic acid blood levels: is there a 
link with dietary intake?
Fish and DHA dietary intake are usually evalu-
ated through the administration of food-frequency 
questionnaires. Measuring dietary DHA intake is a 
laborious measurement based on self-reported con-
sumption and is subject to high day-to-day variabil-
ity. Conversely, measuring DHA level in the plasma 
is a simple and reliable technique. Hence, it would be 
helpful if dietary DHA intake correlated linearly and 
significantly with plasma DHA. Most epidemiologi-
cal studies have shown a positive association between 
fish consumption and lower risk of AD, yet the results 
from blood samples are more mitigated, as reviewed 
previously [39,59]. The discrepancy of the results may 
be partly explained by a lack of an established refer-
ence lipid class in the blood, because studies have been 
performed either on DHA in erythrocytes, plasma 
Figure 1. Omega-3 fatty acid dietary supply and brain 
glucose uptake. (A)18F-fluorodeoxyglucose (18F-FDG) 
standardized uptake values (SUVs) were obtained by in 
vivo PET imaging of the whole brain of control (▪; n = 5) 
and omega-3 PUFA deficient rats (○; n = 6). SUVs are 
expressed as measured activity/normalized dose (mean 
± SEM). *Indicates SUVmax at 45 min was significantly 
different between the two groups. (B) A linearization 
of 18F-FDG uptake during the first 80 s following 
18F-FDG infusion was used to calculate the rate of 
brain glucose uptake in the two groups (previously 
unpublished data).
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phospholipid, cholesteryl esters, triglycerides, free 
fatty acids or plasma total lipids. In addition, several 
factors may modify DHA metabolism and hence 
the relationship between dietary and plasma DHA 
concentrations.
We speculate that lower DHA intake in AD patients 
could still be associated with similar plasma DHA con-
centrations as in the healthy elderly [46], because age-
related cognitive decline may be accompanied by a shift 
in the diet-plasma relationship for DHA. It has recently 
been proposed that the relationship between diet and 
plasma DHA is disrupted in carriers of APOE4, but 
may also vary with age, sex or dietary habits [60]. These 
factors were also identified as modulating DHA con-
centrations in erythrocytes following omega-3 PUFA 
supplementation [61]. In this latter study [61], supple-
mentation explained 66% of the variance in omega-3 
PUFA content in the erythrocytes suggesting that 
other factors such as body weight, physical activity, 
age or sex contribute to about one third of the variance 
in DHA.
Post-mortem brain studies
Several studies have used postmortem samples of 
human brain to measure brain DHA concentration in 
AD patients (Figure 2) [59]. As expected due to lower 
DHA dietary intakes observed during age-related 
cognitive decline, some studies have shown that AD 
patients have lower DHA levels in the hippocampus, 
a brain structure implicated in memory and learning 
[62–64]. Similar results were observed in the frontal cor-
tex, which is important for reasoning, attention, plan-
ning and emotions [63,65–69]. Nevertheless, other stud-
ies did not show any modification of DHA content of 
the frontal cortex [70–73] or in other brain regions that 
are also implicated in AD, such as the temporal or pari-
etal lobes and the parahippocampus [62,66–67,70–71,74]. 
In accordance with animal studies, it has been recently 
proposed that an altered composition of lipid rafts in 
human frontal cortex, including a decrease in their 
DHA content, may be related to the neuropathology 
of AD, especially the formation of senile plaques [68,69].
Randomized clinical trials
A recent prospective study showed that daily consump-
tion of an omega-3 PUFA supplement prevented cogni-
tive impairment as measured by MMSE in elderly Chi-
nese [75], but the type or concentration of the omega-3 
PUFA supplement were not specified. Several other 
RCTs showed that DHA-enriched supplements delay 
cognitive decline in elderly with cognitive impairments 
(Table 1) [76–78]. Some of them have suggested that DHA 
supplementation improves cognitive performances 
in elderly with memory complaints [79,80], MCI [81,82] 
and AD [83]. However, other studies do not show any 
cognitive improvement due to DHA supplement in 
AD [84–86].
The discrepancy in the results from RCT may partly 
been explained by the highly heterogeneous protocols 
used, especially considering the dose, the type and the 
duration of the DHA supplementation (Table 1). For 
example, most studies used fish oil as a supplementa-
tion, providing both DHA and eicosapentaenoic acid 
(EPA), with the latter also potentially contributing 
to the preventive effect of fish oil against cognitive 
decline. Moreover, the protective role of DHA against 
age-related cognitive decline may depend on APOE 
genotype [84] and on the degree of cognitive decline at 
baseline, and may be stronger in those with the mildest 
cognitive impairment [85–86,88–91]. This suggests that 
DHA may be more efficient as a preventive interven-
tion rather than as a curative treatment. As we will 
discuss in the following section, we hypothesized that 
age-relative cognitive decline may be accompanied by a 
shift in DHA metabolism in older persons with mem-
ory problems such that they may be less able to benefit 
from DHA-enriched supplements as cognitively 
healthy individuals.
Docosahexaenoic acid metabolism during 
age-related cognitive decline
To attempt to explain the divergent results between 
epidemiological studies and RCT and between various 
RCT, we hypothesized that DHA metabolism may be 
altered during age-related cognitive decline. The devel-
opment of uniformly labelled tracers with stable iso-
topes constitutes a new approach to safely assess DHA 
metabolism in human clinical studies. A 1-month fol-
low-up of a single dose of uniformly carbon-13 labelled 
DHA (13C-DHA) showed that 13C-DHA remained 
longer in the blood of elderly (mean age 76 years) com-
pared with young adults (mean age 27 years) [92]. 13C-
DHA homeostasis also differed between the different 
plasma lipid classes: compared with young adults, 
plasma enrichment in 13C-DHA in elderly was fourfold 
to fivefold higher in triglycerides and free fatty acids 
within hours and twice higher in PL and CE within 
days to weeks following the ingestion of the tracer.
Carrying APOE4 also disrupts DHA metabo-
lism [58,93–94]. The protective role of higher fish con-
sumption or higher blood DHA against age-related 
cognitive decline may not be observed in carriers of 
APOE4 [53–54,95]. Whole body half-life of DHA in the 
healthy elderly was 77% shorter in carriers of APOE4 
compared with the noncarriers [93], due to higher 
β-oxidation of DHA in the APOE4 carriers as mea-
sured by expired 13C-CO
2
 after the ingestion of the 
tracer 13C-DHA. The relationship between dietary 
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Figure 2. Summary of the published literature on docosahexaenoic acid content in (A) the frontal cortex and  
(B) the hippocampus during Alzheimer’s disease.Bars show docosahexaenoic acid values as a percentage of age-
matched healthy elderly groups for each study shown. Date were obtained from either brain phospholipids (gray 
bars), brain free fatty acids (white bars) or lipid raft fractions (black bars). 
*Studies presenting a significant difference between control and Alzheimer’s disease.
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Table 1. Impact of docosahexaenoic acid supplementation in elderly with cognitive complaints, mild cognitive 
impairment or Alzheimer’s disease.
Cognitive 
status
Age 
(years)
Duration 
(months)
n Supplement Results compared to placebo Ref.
MCI >60 12 18 Placebo   [87]
   17 1290 mg DHA + 450 mg EPA ↑ Memory improvement  
AD >55 12 12 Placebo   [83]
   11 675 mg DHA + 975 EPA Less ↓ in IADL  
   11 675 mg DHA + 975 mg EPA + 600 
mg LA
Less ↓ in MMSE and IADL  
MC 50–90 4 62 Placebo   [88]
   60 300 mg PS + 79 mg DHA + EPA 
(DHA:EPA ratio of 3:1)
↑ Immediate recall compared to P; 
Greater ↑ in subgroup with higher 
baseline cognitive performances
 
MC 50–90 4/4 60 Placebo / 100 mg PS + 26 mg DHA + 
EPA (DHA:EPA ratio of 3:1)
↑ Cognitive performances 
(sustained attention and memory 
recognition)
 [79]
  4/4  300 mg PS + 79 mg DHA + EPA/100 
mg PS + 26 mg DHA + EPA 
(DHA:EPA ratio of 3:1)
Maintained cognitive 
performances
 
AD Mean 76 18 112 Placebo  [84]
   152  2g Algal DHA containing 45–55% 
of DHA
No change on cognitive decline 
and brain atrophy
 
C >65 6 28 Placebo   [89]
   29 180 mg DHA + 120 mg EPA Less ↓ in AMT scores  
MCI >65 6 71 Placebo   
   71 180 mg DHA + 120 mg EPA No change  
MCI 55–90 6 6 Placebo   [85]
   12 1080 mg EPA + 720 mg DHA Significant ↑ in ADAS-Cog score  
AD 55–90 6 9 Placebo   
   8 1080 mg EPA + 720 mg DHA No change  
MC >55 6 218 Placebo  [80]
   219 900 mg DHA ↑ Cognitive performances in 
CANTAB
 
AD Mean 74 6/6 85 Placebo /1.7 g DHA +0.6 g EPA Less ↓ in MMSE score in subgroup 
with very mild AD
[90]
  12 89 1.7 g DHA + 0.6 g EPA Less 6-month ↓ in MMSE score in 
subgroup with very mild AD
 
MCI >65 6 11 Placebo  [82]
   16 1.55 g DHA + 0.4 g EPA ↑ GDS score and verbal fluency  
   13 1.67 g EPA + 0.16 g DHA ↑ GDS score  
MCI Mean 70 3 9 Placebo  [86]
 Mean 67 3 12 240 mg DHA and ARA + antioxidant ↑ Immediate memory and 
attention
 
AMT: Abbreviated Mental Test; AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale–Cognitive; C: Control;  
CANTAB: Cambridge Neuropsychological Test Automated Battery; D: Dementia; DHA: Docosahexaenoic acid; GDS: Geriatric depression scale;  
IADL: Instrumental activities of daily living; MC: Memory complaints; MCI: Mild cognitive impairment.
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and plasma DHA therefore seems to shift in carriers 
of APOE4, who need higher dietary fish intakes to 
increase plasma DHA concentration [60]. In carriers of 
APOE4, β-oxidation may preferentially affect omega-3 
PUFA compared with monounsaturated or saturated 
fatty acids, explaining the modification of DHA 
metabolism occurring with APOE4 [96,97].
Daily dietary intake of DHA has been estimated to be 
lower in many populations than the 250 mg/day recom-
mended [98]. At the same time, a higher intake of DHA 
may also modify its own metabolism. In a recent study, 
the metabolism of 13C-DHA in older adults (mean age 
72 years) was followed before and in the last month of 
a 5-month supplementation providing 1.4 g of DHA 
and 1.8 g of EPA daily [99]. While on the supplement, 
DHA clearance from plasma was faster and β-oxidation 
of 13C-DHA was 87% higher compared with before 
the supplement. However, the kinetics of 13C-DHA in 
APOE4 carriers while on the supplement was not the 
same [59]. APOE4 carriers also present a lower plasma 
response to a 6-week supplementation with 3 g/day of 
DHA + EPA compared with noncarriers [94]. Aging 
alone also disrupts DHA homeostasis following short-
term supplementation with fish oil; compared with 
young adult, plasma DHA concentration was indeed 
increased 42% more in elderly [100].
The PET tracer, 11C-DHA, has permitted the esti-
mation of brain DHA turnover of 4 mg/day and a 
brain DHA half-life of 2.5 years [101]. DHA kinetics 
in the brain are therefore clearly different from those 
of the whole-body, because the latter is estimated 
to be 32 days in carriers of APOE4 and 140 days in 
noncarriers of APOE4 [93]. The study of brain DHA 
homeostasis using PET imaging may therefore provide 
some useful information on genotype- and diet-related 
modifications to DHA during aging [102]. Postmor-
tem studies of brain from AD patients show a linear 
relationship between apoE and DHA concentrations 
[103], suggesting a role of apoE protein and indirectly 
in APOE4 genotype, in the maintenance of DHA 
concentrations within the brain. It was recently shown 
that omega-3 PUFA provided through the diet cross 
the blood–brain barrier and increase DHA content 
in the cerebrospinal fluid in AD [104]. Moreover, the 
recent finding of an efficient transporter for DHA into 
the brain [105] provides new field of investigation to 
better understand DHA homeostasis in the brain.
Hence, DHA metabolism is influenced by two 
important risk factors for AD – aging and APOE4. 
This may suggest that a shift in DHA homeostasis dur-
ing age-related cognitive decline, especially AD, may 
contribute to the divergent results obtained in RCT 
studies. A modification of DHA metabolism during 
AD has been reported previously, especially an increase 
in peroxidation products [106], even in the early stages 
of age-related cognitive decline [107]. This effect was 
lower when participants had higher omega-3 PUFA 
dietary intakes [87]. Further studies are needed to better 
characterize the link between risk of AD and whole 
body and brain metabolism of DHA.
Conclusion
Animal and in vitro studies provide some promising 
results on the role played by DHA in the prevention 
of age-related cognitive decline. DHA may help pre-
vent the formation of senile plaques and neurofibril-
lary tangles and may also help maintain brain glucose 
uptake during aging. Nevertheless, differences in DHA 
synthesis and metabolism have been observed between 
animals and humans. Humans have lower endogenous 
synthesis of DHA from ALA compared with animals. 
Moreover, the human brain strongly retains DHA in 
membrane phospholipids despite very low DHA dietary 
intakes. The promising protective effect of DHA 
observed in cellular and animal models has yet to be 
widely confirmed in clinical studies. The consumption 
of fatty fish and DHA has been mostly reported to have 
a protective role against cognitive decline and AD, but 
results obtained from blood or brain samples do not help 
explain this protective effect. The use of isotopically 
Cognitive 
status
Age 
(years)
Duration 
(months)
n Supplement Results compared to placebo Ref.
AD Mean 67 3 8 240 mg DHA and ARA + antioxidant No change  
C 67–92 6 8 600 mg DHA + 500 mg EPA 75% of the subjects had cognitive 
improvements
[91]
D 67–92 6 22 600 mg DHA + 500 mg EPA 55% of the subjects had cognitive 
improvements
 
AMT: Abbreviated Mental Test; AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale–Cognitive; C: Control;  
CANTAB: Cambridge Neuropsychological Test Automated Battery; D: Dementia; DHA: Docosahexaenoic acid; GDS: Geriatric depression scale;  
IADL: Instrumental activities of daily living; MC: Memory complaints; MCI: Mild cognitive impairment.
Table 1. Impact of docosahexaenoic acid supplementation in elderly with cognitive complaints, mild cognitive 
impairment or Alzheimer’s disease (cont.).
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labeled tracers highlights some modifications in DHA 
metabolism due to healthy aging, APOE4 genotype 
and dietary intakes that should be considered in future 
clinical studies. Understanding the complexity of DHA 
metabolism during age-related cognitive decline such as 
AD is essential to improve and adapt dietary strategies 
to this large and vulnerable population.
Future perspective
The use of uniformly labeled tracers has allowed 
great advances in understanding DHA kinetics dur-
ing aging. Recent studies have shown that 13C-DHA 
metabolism differs depending on age, APOE genotype 
and dietary intake. Nevertheless, to fully understand 
the protective role of omega-3 PUFA against AD and 
adapt dietary recommendations in this population, 
several points remained to be clarified in the future:
•	 13C-DHA homeostasis should be evaluated in AD;
•	 Supplementation with omega-3 fatty acids are 
mainly done using fish oil, which is enriched in 
both DHA and EPA. The further study of EPA 
metabolism during aging and AD and its relation-
ship with dietary intakes will provide useful infor-
mation to understand whether protective role of 
fish oil against AD can be optimized and observed 
more consistently;
•	 The recent discovery of a brain DHA transporter [105] 
and the use of PET imaging will bring new information 
on DHA homeostasis in the brain and may be helpful 
to develop nutritional strategies adapted to favor 
DHA incorporation within the brain;
•	 The mechanisms associated with the protective 
role of DHA against cognitive decline and AD 
remained to be fully characterized in humans, 
especially the role of DHA in brain glucose metab-
olism. PET imaging tracers such as 18F-FDG or 
11C-PIB, a marker of senile plaques, will help 
improve our understanding of the relationship 
between omega-3 dietary intake and brain glucose 
hypometabolism and amyloid deposition.
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Executive summary
Omega-3 fatty acids & the neuropathology of AD (Alzheimer’s diesease): evidence from in vitro & animal 
studies
•	 DHA has a protective role against Aβ accumulation and toxicity.
•	 DHA reduces the hyperphosphorylation of Tau proteins, associated with the formation of neurofibrillary 
tangles.
•	 DHA play a key role in the regulation of brain glucose metabolism.
Omega-3 fatty acids & prevention of AD in humans: epidemiological studies vs clinical trials
•	 Epidemiological studies suggest that higher consumption of fatty fish enriched in docosahexaenoic acid (DHA) 
prevents age-related cognitive decline and the development of AD.
•	 The relationship between dietary and plasma DHA during AD is complex and influenced by several factors 
such as age, sex, APOE4 genotype, body weight or physical activity.
•	 Postmortem brain studies show a reduced amount of DHA in the hippocampus but not necessarily in the 
cortex of AD patients compared with cognitively healthy control.
•	 Results from RCT are inconsistent but broadly suggest that DHA consumption may be more efficient as a 
preventive strategy against cognitive decline rather than as a curative strategy in AD.
DHA metabolism during age-related cognitive decline
•	 Healthy aging is associated with a slower clearance of plasma DHA.
•	 Carrying the APOE4 allele is the main genetic factor of sporadic AD and is associated with higher β-oxidation 
of DHA and lower whole-body half-life of DHA compared with the noncarriers.
•	 DHA metabolism is influenced by omega-3 polyunsaturated fatty acids (PUFA) intake and the response to a 
supplementation in omega-3 PUFA differs between carriers and noncarriers of APOE4.
•	 Uniformly-labeled tracers of omega-3 PUFA are innovative and useful tools to better understand DHA 
metabolism during aging and AD.
www.futuremedicine.com 99future science group
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